Table 2. Open in new tab Characteristics...

Characteristics	No inpatient COVID hospitalization (n = 102 567)	Inpatient COVID hospitalization (n = 419)	P value
Demographics
Age, y	53.3	17.10	68.1	15.20	<.001
Female	55 904	54.5%	231	55.1%	.80
Comorbidities in prior 6 mo (% yes)
Obesity	16 793	16%	116	28%	<.001
Type 2 diabetes	14 147	14%	153	37%	<.001
Cancer	13 609	13%	96	23%	<.001
Chronic obstructive pulmonary disease	8106	8%	116	28%	<.001
Chronic kidney disease	19 660	19%	187	45%	<.001
Cardiovascular disease	7922	8%	126	30%	<.001
Asthma	6286	6%	35	8%	.058
Cerebrovascular disease	4591	4%	63	15%	<.001
Thromboembolic event	4566	4%	53	13%	<.001
Sickle cell disease	77	0%	≤10
Pregnancy	1136	1%	≤10
Smoking	16 347	16%	136	32%	<.001
Use of medications (in 90 d prior to cohort entry)
No treatment	25 417	25%	121	29%	.053
Anti-TNF	13 836	13%	32	8%	<.001
Anti-TNF and azathioprine/6-MP	1996	2%	≤10
Anti-TNF and methotrexate	856	1%	≤10
Vedolizumab	5533	5%	18	4%	.3203
Ustekinumab	2754	3%	11	3%	.9398
Tofacitinib	344	0%	≤10
Systemic corticosteroids	11 113	11%	76	18%	<.001
5-ASA/sulfasalazine	21 139	21%	69	16%	.036
Azathioprine/6-MP	10 028	10%	36	9%	.41
Methotrexate	1787	2%	≤10
Budesonide (oral)	2788	3%	11	3%	.91
Proton pump inhibitor	288	0%	≤10
Health care service utilization intensity
Number of ambulatory encounters in prior 6 mo	11.1	10.20	15.7	12.50	<.001

Characteristics

No inpatient COVID hospitalization (n = 102 567)

Inpatient COVID hospitalization (n = 419)

P value

n/Mean

%/SD

n/Mean

%/SD

Demographics

Age, y

53.3

17.10

68.1

15.20

<.001

Female

55 904

54.5%

231

55.1%

.80

Comorbidities in prior 6 mo (% yes)

Obesity

16 793

16%

116

28%

<.001

Type 2 diabetes

14 147

14%

153

37%

<.001

Cancer

13 609

13%

23%

<.001

Chronic obstructive pulmonary disease

8106

116

28%

<.001

Chronic kidney disease

19 660

19%

187

45%

<.001

Cardiovascular disease

7922

126

30%

<.001

Asthma

6286

.058

Cerebrovascular disease

4591

15%

<.001

Thromboembolic event

4566

13%

<.001

Sickle cell disease

≤10

Pregnancy

1136

≤10

Smoking

16 347

16%

136

32%

<.001

Use of medications (in 90 d prior to cohort entry)

No treatment

25 417

25%

121

29%

.053

Anti-TNF

13 836

13%

<.001

Anti-TNF and azathioprine/6-MP

1996

≤10

Anti-TNF and methotrexate

856

≤10

Vedolizumab

5533

.3203

Ustekinumab

2754

.9398

Tofacitinib

344

≤10

Systemic corticosteroids

11 113

11%

18%

<.001

5-ASA/sulfasalazine

21 139

21%

16%

.036

Azathioprine/6-MP

10 028

10%

.41

Methotrexate

1787

≤10

Budesonide (oral)

2788

.91

Proton pump inhibitor

288

≤10

Health care service utilization intensity

Number of ambulatory encounters in prior 6 mo

11.1

10.20

15.7

12.50

<.001

Characteristics	No inpatient COVID hospitalization (n = 102 567)	Inpatient COVID hospitalization (n = 419)	P value
Demographics
Age, y	53.3	17.10	68.1	15.20	<.001
Female	55 904	54.5%	231	55.1%	.80
Comorbidities in prior 6 mo (% yes)
Obesity	16 793	16%	116	28%	<.001
Type 2 diabetes	14 147	14%	153	37%	<.001
Cancer	13 609	13%	96	23%	<.001
Chronic obstructive pulmonary disease	8106	8%	116	28%	<.001
Chronic kidney disease	19 660	19%	187	45%	<.001
Cardiovascular disease	7922	8%	126	30%	<.001
Asthma	6286	6%	35	8%	.058
Cerebrovascular disease	4591	4%	63	15%	<.001
Thromboembolic event	4566	4%	53	13%	<.001
Sickle cell disease	77	0%	≤10
Pregnancy	1136	1%	≤10
Smoking	16 347	16%	136	32%	<.001
Use of medications (in 90 d prior to cohort entry)
No treatment	25 417	25%	121	29%	.053
Anti-TNF	13 836	13%	32	8%	<.001
Anti-TNF and azathioprine/6-MP	1996	2%	≤10
Anti-TNF and methotrexate	856	1%	≤10
Vedolizumab	5533	5%	18	4%	.3203
Ustekinumab	2754	3%	11	3%	.9398
Tofacitinib	344	0%	≤10
Systemic corticosteroids	11 113	11%	76	18%	<.001
5-ASA/sulfasalazine	21 139	21%	69	16%	.036
Azathioprine/6-MP	10 028	10%	36	9%	.41
Methotrexate	1787	2%	≤10
Budesonide (oral)	2788	3%	11	3%	.91
Proton pump inhibitor	288	0%	≤10
Health care service utilization intensity
Number of ambulatory encounters in prior 6 mo	11.1	10.20	15.7	12.50	<.001

Table 2.

Open in new tab

Characteristics of the population by inpatient COVID-19 hospitalization

Characteristics	No inpatient COVID hospitalization (n = 102 567)		Inpatient COVID hospitalization (n = 419)		P value
Characteristics	n/Mean	%/SD	n/Mean	%/SD	P value
Demographics
Age, y	53.3	17.10	68.1	15.20	<.001
Female	55 904	54.5%	231	55.1%	.80
Comorbidities in prior 6 mo (% yes)
Obesity	16 793	16%	116	28%	<.001
Type 2 diabetes	14 147	14%	153	37%	<.001
Cancer	13 609	13%	96	23%	<.001
Chronic obstructive pulmonary disease	8106	8%	116	28%	<.001
Chronic kidney disease	19 660	19%	187	45%	<.001
Cardiovascular disease	7922	8%	126	30%	<.001
Asthma	6286	6%	35	8%	.058
Cerebrovascular disease	4591	4%	63	15%	<.001
Thromboembolic event	4566	4%	53	13%	<.001
Sickle cell disease	77	0%	≤10
Pregnancy	1136	1%	≤10
Smoking	16 347	16%	136	32%	<.001
Use of medications (in 90 d prior to cohort entry)
No treatment	25 417	25%	121	29%	.053
Anti-TNF	13 836	13%	32	8%	<.001
Anti-TNF and azathioprine/6-MP	1996	2%	≤10
Anti-TNF and methotrexate	856	1%	≤10
Vedolizumab	5533	5%	18	4%	.3203
Ustekinumab	2754	3%	11	3%	.9398
Tofacitinib	344	0%	≤10
Systemic corticosteroids	11 113	11%	76	18%	<.001
5-ASA/sulfasalazine	21 139	21%	69	16%	.036
Azathioprine/6-MP	10 028	10%	36	9%	.41
Methotrexate	1787	2%	≤10
Budesonide (oral)	2788	3%	11	3%	.91
Proton pump inhibitor	288	0%	≤10
Health care service utilization intensity
Number of ambulatory encounters in prior 6 mo	11.1	10.20	15.7	12.50	<.001

Characteristics	No inpatient COVID hospitalization (n = 102 567)		Inpatient COVID hospitalization (n = 419)		P value
Characteristics	n/Mean	%/SD	n/Mean	%/SD	P value
Demographics
Age, y	53.3	17.10	68.1	15.20	<.001
Female	55 904	54.5%	231	55.1%	.80
Comorbidities in prior 6 mo (% yes)
Obesity	16 793	16%	116	28%	<.001
Type 2 diabetes	14 147	14%	153	37%	<.001
Cancer	13 609	13%	96	23%	<.001
Chronic obstructive pulmonary disease	8106	8%	116	28%	<.001
Chronic kidney disease	19 660	19%	187	45%	<.001
Cardiovascular disease	7922	8%	126	30%	<.001
Asthma	6286	6%	35	8%	.058
Cerebrovascular disease	4591	4%	63	15%	<.001
Thromboembolic event	4566	4%	53	13%	<.001
Sickle cell disease	77	0%	≤10
Pregnancy	1136	1%	≤10
Smoking	16 347	16%	136	32%	<.001
Use of medications (in 90 d prior to cohort entry)
No treatment	25 417	25%	121	29%	.053
Anti-TNF	13 836	13%	32	8%	<.001
Anti-TNF and azathioprine/6-MP	1996	2%	≤10
Anti-TNF and methotrexate	856	1%	≤10
Vedolizumab	5533	5%	18	4%	.3203
Ustekinumab	2754	3%	11	3%	.9398
Tofacitinib	344	0%	≤10
Systemic corticosteroids	11 113	11%	76	18%	<.001
5-ASA/sulfasalazine	21 139	21%	69	16%	.036
Azathioprine/6-MP	10 028	10%	36	9%	.41
Methotrexate	1787	2%	≤10
Budesonide (oral)	2788	3%	11	3%	.91
Proton pump inhibitor	288	0%	≤10
Health care service utilization intensity
Number of ambulatory encounters in prior 6 mo	11.1	10.20	15.7	12.50	<.001

Abbreviations: 5-ASA, 5-aminsalicylate; 6-MP, 6-mercaptopurine; anti-TNF, anti-tumor necrosis factor α; IBD, inflammatory bowel disease.

This Feature Is Available To Subscribers Only